title: Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia.
abstract: Measurement of tau-protein and beta-amyloid(1-42 )(Abeta42) in cerebrospinal fluid (CSF) has gained increasing acceptance in the differential diagnosis of Alzheimer's disease. We investigated CSF tau-protein and Abeta42 concentrations in 73 patients with advanced idiopathic Parkinson's disease with dementia (PDD) and 23 patients with idiopathic Parkinson's disease without dementia (PD) and in a comparison group of 41 non-demented neurological patients (CG) using commercially available enzyme-linked-immunoabsorbant-assay (ELISA). tau-Protein levels were statistically significantly higher and Abeta42 lower in the PDD patients compared to PD patients and the CG. This observation was most marked (p < 0.05) in a subgroup of patients with PDD carrying the apolipoprotein genotype epsilon3/epsilon3. The distribution of the apolipoprotein genotypes in PDD and PD patients was similar to that of the CG. Although a significant difference in tau-protein values was observed between PDD and CG, no diagnostic cut-off value was established. These findings suggest that such protein CSF changes may help to support the clinical diagnosis of cognitive decline in PD and that there may be apolipoprotein-E-isoform-specific differences in CSF protein regulation in advanced PDD.
authors.affiliation: Department of Neurology,Georg-August University, Kassel, Germany. bmollenhauer@ics.bwh.harvard.edu
authors.forename: Brit
authors.initials: B
authors.lastname: Mollenhauer
authors.forename: Claudia
authors.initials: C
authors.lastname: Trenkwalder
authors.forename: Nicolas
authors.initials: N
authors.lastname: von Ahsen
authors.forename: Mirko
authors.initials: M
authors.lastname: Bibl
authors.forename: Petra
authors.initials: P
authors.lastname: Steinacker
authors.forename: Peter
authors.initials: P
authors.lastname: Brechlin
authors.forename: Jan
authors.initials: J
authors.lastname: Schindehuette
authors.forename: Sigrid
authors.initials: S
authors.lastname: Poser
authors.forename: Jens
authors.initials: J
authors.lastname: Wiltfang
authors.forename: Markus
authors.initials: M
authors.lastname: Otto
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D001057:Apolipoproteins E / Q000235:genetics; D003704:Dementia / Q000134:cerebrospinal fluid* / Q000209:etiology* / Q000523:psychology; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000134:cerebrospinal fluid* / Q000150:complications* / Q000523:psychology; D010446:Peptide Fragments / Q000134:cerebrospinal fluid*; D011569:Psychiatric Status Rating Scales; D051844:alpha-Synuclein / Q000134:cerebrospinal fluid; D016875:tau Proteins / Q000134:cerebrospinal fluid*
chemical_list: D016229:Amyloid beta-Peptides; D001057:Apolipoproteins E; D010446:Peptide Fragments; D051844:alpha-Synuclein; C075222:amyloid beta-protein (1-42); D016875:tau Proteins